Verséa Ophthalmics launches tear-based, point-of-care immunoassay kit for ocular disease
Click Here to Manage Email Alerts
Verséa Ophthalmics announced the distribution of its T-POC Total IgE Immunoassay Kit, a tear-based point-of-care test for the diagnosis and management of ocular surface disease.
According to a company press release, the T-POC Total IgE Immunoassay Kit measures actual levels of IgE, a known biomarker linked to allergic conjunctivitis. The test, developed and manufactured by partner Axim Biotechnologies, is designed to help clinicians distinguish allergic disease from other conditions such as dry eye or infectious conjunctivitis. Repetition of the test after initiating treatment may help determine therapeutic response.
“Clinical symptoms frequently overlap among various conditions, making it a clinical challenge to accurately diagnose using only symptoms and traditional diagnostics,” Rob Sambursky, MD, president of Verséa Ophthalmics, said in the release. “Providing a specific number representing a disease state to the doctor will empower the eye care professional to make the best-informed treatment decision for his or her patients and allow them to be better followed and managed over time.”
The company plans to launch the next phase of its testing platform in the coming weeks, which will include T-POC Lactoferrin, a test for aqueous-deficient dry eye disease.
“After years of research and development, we are excited that Verséa Ophthalmics, our global exclusive commercial partner, is effectively making our advanced testing solutions accessible to better diagnose patients suffering from ocular surface disease,” John Huemoeller II, CEO of AXIM Biotechnologies, said in the release.
Perspective
Back to Top
Because a myriad of ocular surface and tear film disorders such as dry eye disease (DED), ocular allergy, blepharitis, meibomian gland dysfunction and conjunctivitis can produce similar symptoms, it can be difficult to differentiate based on symptoms alone. Also, current testing procedures can be inadequate for the differential diagnosis of ocular surface disorders based on the multifactorial etiology.
Having standardized tests to aid in the diagnosis of DED, as well as monitoring treatment efficacy, is crucial to providing effective care. By releasing the T-POC Total IgE Immunoassay and Lateral Flow reader, Verséa has provided practices with greater diagnostic abilities to determine causality and a new framework for rapid testing that clinicians can incorporate easily into their office flow.
Read more about
Click Here to Manage Email Alerts